SiranBio raises nearly CNY 400 million in Pre-A, A and A+ rounds, Suzhou Angel Guidance Fund says
PUBT · 1d ago
Share
Listen to the news
- Suzhou Angel Venture Capital Guidance Fund Management-backed SiranBio closed an A-round series totaling nearly CNY 400 million.
- China-based biotech develops siRNA drugs, positioning around dual-target candidates, extrahepatic delivery, antiviral, metabolic disease programs.
- Company said combined equity financing, licensing-related receipts brought cumulative R&D funding to nearly CNY 1 billion.
- Lead asset SA1211 targets functional cure for hepatitis B; Phase Ib ongoing; Phase II expected in early 2027.
- Second program SA030 is an extrahepatic fat-targeted siRNA partnered with GSK for global development; in clinical-stage development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Angel Venture Capital Guidance Fund Management Co Ltd published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending